BIOGEN INC. Realized Investment Gains (Losses)
BIOGEN INC. (BIIB) reported Realized Investment Gains (Losses) of $22.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2026-04-29
- BIOGEN INC. realized investment gains (losses) for the quarter ending 2026-03-31 was $22.30M.
- BIOGEN INC. realized investment gains (losses) for the quarter ending 2025-09-30 was -$3.80M, a 109.72% decline year-over-year.
- BIOGEN INC. realized investment gains (losses) for the quarter ending 2025-06-30 was $5.30M.
- BIOGEN INC. realized investment gains (losses) for the quarter ending 2025-03-31 was -$35.60M.
- BIOGEN INC. realized investment gains (losses) for fiscal 2020 was $12.10M, a 75.80% decline from fiscal 2019.
- BIOGEN INC. realized investment gains (losses) for fiscal 2019 was $50.00M.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $22.30M 10-Q · filed 2026-04-29 | |||
| 2025-09-30 | -$3.80M 10-Q · filed 2025-10-30 | $1.50M derived: sum of 2 quarters · filed 2025-10-30 | -$34.10M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $5.30M 10-Q · filed 2025-07-31 | -$30.30M 10-Q · filed 2025-07-31 | ||
| 2025-03-31 | -$35.60M 10-Q · filed 2026-04-29 | |||
| 2024-09-30 | $39.10M 10-Q · filed 2025-10-30 | $8.40M derived: sum of 2 quarters · filed 2025-10-30 | -$22.20M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | -$30.70M 10-Q · filed 2025-07-31 | -$61.30M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$30.60M 10-Q · filed 2025-05-01 | |||
| 2023-09-30 | -$317.30M 10-Q · filed 2024-10-30 | -$211.90M derived: sum of 2 quarters · filed 2024-10-30 | -$289.60M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $105.40M 10-Q · filed 2024-08-01 | $27.70M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | -$77.70M 10-Q · filed 2024-04-24 | |||
| 2022-09-30 | $101.80M 10-Q · filed 2023-11-08 | $23.60M derived: sum of 2 quarters · filed 2023-11-08 | -$167.50M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$78.20M 10-Q · filed 2023-07-25 | -$269.30M 10-Q · filed 2023-07-25 | ||
| 2022-03-31 | -$191.10M 10-Q · filed 2023-04-25 | |||
| 2021-09-30 | -$424.50M 10-Q · filed 2022-10-25 | -$270.60M derived: sum of 2 quarters · filed 2022-10-25 | -$707.20M 10-Q · filed 2022-10-25 | -$642.50M derived: sum of 4 quarters · filed 2022-10-25 |
| 2021-06-30 | $153.90M 10-Q · filed 2022-07-20 | -$282.70M 10-Q · filed 2022-07-20 | -$218.00M derived: sum of 3 quarters · filed 2022-07-20 | -$300.10M derived: sum of 4 quarters · filed 2022-07-20 |
| 2021-03-31 | -$436.60M 10-Q · filed 2022-05-03 | -$371.90M derived: sum of 2 quarters · filed 2022-05-03 | -$454.00M derived: sum of 3 quarters · filed 2022-05-03 | -$347.20M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $64.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$17.40M derived: sum of 2 quarters · filed 2021-10-20 | $89.40M derived: sum of 3 quarters · filed 2021-10-20 | $12.10M 10-K · filed 2021-02-03 |
| 2020-09-30 | -$82.10M 10-Q · filed 2021-10-20 | $24.70M derived: sum of 2 quarters · filed 2021-10-20 | -$52.60M 10-Q · filed 2021-10-20 | -$201.50M derived: sum of 4 quarters · filed 2021-10-20 |
| 2020-06-30 | $106.80M 10-Q · filed 2021-07-22 | $29.50M 10-Q · filed 2021-07-22 | -$119.40M derived: sum of 3 quarters · filed 2021-07-22 | -$123.50M derived: sum of 4 quarters · filed 2021-07-22 |
| 2020-03-31 | -$77.30M 10-Q · filed 2021-04-22 | -$226.20M derived: sum of 2 quarters · filed 2021-04-22 | -$230.30M derived: sum of 3 quarters · filed 2021-04-22 | -$403.70M derived: sum of 4 quarters · filed 2021-04-22 |
| 2019-12-31 | -$148.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$153.00M derived: sum of 2 quarters · filed 2021-02-03 | -$326.40M derived: sum of 3 quarters · filed 2021-02-03 | $50.00M 10-K · filed 2021-02-03 |
| 2019-09-30 | -$4.10M 10-Q · filed 2020-10-21 | -$177.50M derived: sum of 2 quarters · filed 2020-10-21 | $198.90M 10-Q · filed 2020-10-21 | |
| 2019-06-30 | -$173.40M 10-Q · filed 2020-07-22 | $203.00M 10-Q · filed 2020-07-22 | ||
| 2019-03-31 | $376.40M 10-Q · filed 2020-04-23 | |||
| 2018-09-30 | $141.10M 10-Q · filed 2019-10-22 | $146.40M derived: sum of 2 quarters · filed 2019-10-22 | $132.00M 10-Q · filed 2019-10-22 | |
| 2018-06-30 | $5.30M 10-Q · filed 2019-07-24 | -$9.10M 10-Q · filed 2019-07-24 | ||
| 2018-03-31 | -$14.40M 10-Q · filed 2019-04-24 | |||
| 2017-09-30 | -$4.00M 10-Q · filed 2018-10-23 | -$17.40M derived: sum of 2 quarters · filed 2018-10-23 | -$15.00M 10-Q · filed 2018-10-23 | |
| 2017-06-30 | -$13.40M 10-Q · filed 2018-07-24 | -$11.00M 10-Q · filed 2018-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |